Recon: Novartis joins exodus out of antibiotics

• Novartis joins the Big Pharma exodus out of antibiotics, dumping research, cutting 140 and out-licensing programs (Endpoints) (Bloomberg) (Fierce)
• Nevada Execution Halted on Drugmaker’s Lawsuit (WSJ) (NYT) (Reuters)
• Top Dem demands more details on pricing deal between Pfizer and Trump (The Hill) (STAT-$)
• Zogenix's seizure drug clears late-stage trial, shares soar (Reuters) (STAT) (Endpoints) (Fierce)
• REPORT: 1.6 Billion Opioid Doses Poured Into Missouri Over 6 Years (NPR) (STAT)
• Compass Therapeutics Closes on Series A Financing Totaling $132 Million (BioSpace) (Fierce)
• CMS proposes $190 million raise for dialysis centers (Modern Healthcare) (Healthcare Finance)
• Qiagen Accused in Suit of Trade-Secret Theft, Infringement (Bloomberg-$) (GenomeWeb)
• Is DEA Being Forced To Reschedule The CBD Compound? (Forbes) (Chicago Sun Times)
• Oyster Point Looks To Compete In Dry Eye With Nasal Spray Therapeutic (Scrip-$) (Endpoints)

• Exclusive: With U.S. trade under a cloud, China opens to Indian pharma (Reuters) (Global Times)
• China's appetite for infrastructure investment creates big winners (Nikkei Asian Review)
• GSK Sells Psoriasis/Dermatitis Candidate Tapinarof to Dermavant (GEN) (BioPharma Dive)
• Merck inks deal with China's Xian Janssen for type 2 diabetes drug (BioSpace) (Fierce) (EPR)
• Genmab pays Immatics $54M to form anticancer bispecific pact (Fierce) (GEN) (Endpoints)
• Was pharma bold enough at Lions Health 2018? (pharmaphorum)
• Brazil prosecutors allege jailed GE executive helped company partake in medical cartel (Reuters)
• WHO seeks access to Syrians dying from heat, disease in south (Reuters)
• Changes to Chinese Medical Device Regulations would Benefit Foreign Manufacturers (Emergo Group)

• The drug pricing playbook: how pharma companies keep costs high (Financial Times)
• Addyi Rises Again (The Hastings Center)
• Perspectives on uncritical NYT coverage of cardiac mitochondrial transplant trial (The Niche)
• A Parallel Universe of Clinical Trials (NEJM)
• With Revlimid and Pomalyst price increases, could Celgene be next on Trump’s to-call list? (Fierce)
• 3 Key Lessons From Trump's Drug Price Feud With Pfizer (Fortune)
• What Pfizer, Trump, and consumers got out of a surprising deal — and what they didn’t (STAT)
• U.S. ended value-based pricing plan for cancer drug because of doubts it would work (STAT-$)
• U.S. Insurers Say the Opioid Crisis Might Be Declining (Fortune)
• Patient Experience: The Future Of Big Pharma Is Software (Forbes)
• Drug Prices Keep Climbing Even as Trump Steps Up Twitter Threats (Bloomberg-$)
• Celgene’s Otezla Drug Patent Dispute Swells N.J. Court Docket (Bloomberg-$)
• Tackling pharma’s predatory research problem (PharmaTimes)
• VC money booms in Q2, with mega-deals hitting record levels (Endpoints)

• Parker Institute scientists herald a cell therapy breakthrough in the lab, using next-gen CRISPR tech to engineer T cells (Endpoints)
• Common Chemotherapy Drug Is More Effective When Given With Dietary Supplement In Mice (Forbes)
• Virus-free CRISPR could mean faster, more precise gene editing for T-cell therapies (Fierce)
• Roche’s Venclexta filed in the US for acute myeloid leukemia (PharmaTimes)
• Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome (Press)

• New Research Provides More Reasons to Repeal the Medical Device Tax (Tax Foundation)
• NAMSA Launches “Uniquely IVD” Development Services to Expedite In Vitro Diagnostic Technology Commercialization Efforts for Global Manufacturers (NAMSA)
• Abbott Receives FDA Approval for Next-Generation MitraClip Device to Treat People with Leaky Heart Valves (Press)
• Medtronic Wins Expanded Indication for SelectSecure MRI SureScan Pacing Lead for His Bundle Site Stimulation (Press)
• Cutting Edge Spine Announces FDA 510(K) Clearance of its New HA Enhanced PEEK Interbody for the Cervical Spine, the EVOL ha-C (Press)

• The Trump Administration Is Making Immigrant Parents Pay $800 for DNA Tests to Get Their Kids Back (NPR)
• DEA aims to stop flow of opioids diverted for abuse (Washington Examiner)
• DEA Finalizes Prescription Opioid Anti-Diversion Policy (Law360-$)
• FCC Announces $100M Telehealth Pilot Program (Law360-$)
• maging technique illuminates immune status of monkeys with HIV-like virus (NIH)
• NIAID scientists create 3D structure of 1918 influenza virus-like particles (NIH)
• Why Monsanto Could Soon Get Hit With a Flood of Cancer-Related Lawsuits (Fortune)
• Michigan Approves 11 New Conditions for Medical Marijuana Treatment (Fortune)
• Democrats refocus fight against Trump's Supreme Court nominee on healthcare (Reuters)
• Drug Discounts for Prisoners Crucial for State Budgets (Bloomberg-$)
• State hits CVS pharmacy benefit company with $1.5 million fine (Courier Journal)
• FDA expands its support for states to advance implementation of produce safety activities (FDA)
• Startups Lead a New Rush Into Obamacare's Now-Profitable Markets (Bloomberg)

• FDA Advisory Committee Calendar

• NICE backs Qarziba for children with high-risk neuroblastoma (PharmaTimes)
• Gerresheimer to acquire Sensile Medical and its drug-delivery tech (DDBN)
• Asahi Intecc to buy RetroVascular for $26m (MassDevice)
• Gopher Completed Guardian ORB System FCC and CE Certification (Press)
• QIAGEN partners with U.K. to expand biomarker research in Manchester (Press)
• Philips signs two long-term strategic partnership agreements in Germany (Press)
• RXB Healthcare Technologies Enters European Market with Acquisition of SPR Global Technologies (Press)
• Updated: Common issues identified during clinical trial applications (MHRA)
• Matt Hancock writes in the Health Service Journal about his admiration for the NHS and its staff. (UK Government)

• Samsung BioLogics to face criminal probe over accounting fraud for biosims JV (Fierce)
• iBio and CC-Pharming to develop biosimilar rituximab (The Pharma Letter)
• A*STAR Institute and Mayo Clinic Identify Key Protein to Convert Skin Cells into Other Types of Cells (BioSpace)
• CStone's PD-1 inhibitor CS1003 receives clinical trial approval in China (Press)

• Commonly used antibiotic in India under USFDA lens (Times of India)
• NPPA fixes retail prices of 6 formulations (NPPA)

• Montelukast: Safety Review (TGA)
• TGA presentations: The new Code - where are we at? 12 & 13 June 2018 (TGA)

• Thousands of local patients affected by recall of contaminated heart drug (Windsor Star)
• Protecting Patents in Canada • Common Rule Recommendations (Bloomberg-$)
• Updated: Application Form for Custom-Made Devices and Medical Devices for Special Access (Health Canada)
• Notice of intent to amend: Prescription Drug List (PDL): Phytocannabinoids (Health Canada)

• Few U.S. women have serious complications after abortions (Reuters)
• Everyone deserves a holistic, patient-centric health care system (STAT)
• How Bundling Care Hurts The Patients Who Need It The Most (Forbes)